Combination pharmaceutical composition and treatment method

JPWO2022102715A5Inactive Publication Date: 2024-11-13
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022562178
Authority / Receiving Office
JP · JP
Patent Type
Applications
Priority Date
2021-11-11
Filing Date
2021-11-11
Publication Date
2024-11-13
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cancer treatments using BTK inhibitors and immune checkpoint inhibitors have limited effectiveness and resistance issues, with no reported synergistic antitumor effects when used in combination with reversible BTK inhibitors.

Method used

A pharmaceutical composition combining a reversible BTK inhibitor, such as oxoisoquinoline derivatives or triazine derivatives, with an immune checkpoint inhibitor like anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibodies, to enhance antitumor immunity and therapeutic effects.

Benefits of technology

The combination of reversible BTK inhibitors and immune checkpoint inhibitors demonstrates synergistic anticancer effects, effectively suppressing tumor growth and inducing complete tumor regression in mouse models, offering a more effective cancer treatment option than using either alone.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2022102715000001
    Figure 2022102715000001
  • Figure 2022102715000002
    Figure 2022102715000002
Patent Text Reader

Abstract

Provided is a novel cancer treatment means in which a reversible BTK inhibitor and an immunity checkpoint inhibitor are combined. For example, provided is a pharmaceutical composition for treating cancer wherein BTK inhibitor (I-A) and an anti PD-1 antibody are combined.
Need to check novelty before this filing date? Find Prior Art

Description

Combination Pharmaceutical Compositions and Methods of Treatment

[0001] The present invention relates to a pharmaceutical composition for cancer treatment comprising a combination of a reversible BTK inhibitor and an immune checkpoint inhibitor, and a method for cancer treatment using said composition.

[0002] Bruton's tyrosine kinase (BTK) is a member of the Tec family of non-receptor tyrosine kinases and is an important signal transduction enzyme expressed in all hematopoietic cell types except T lymphocytes and natural killer cells. BTK is a key regulator of B cell survival, differentiation, proliferation, and activation, and plays a crucial role in B cell signal transduction (Non-Patent Documents 1 and 2). The B cell receptor (BCR) on the cell surface transmits signals into the cell via BTK, which is located downstream of BCR. Therefore, abnormal activation of the B cell signaling pathway is thought to promote the proliferation and survival of cancer cells, such as B cell lymphoma and chronic lymphocytic leukemia (Non-Patent Document 3). BTK is also known to play an important role in numerous other cell signaling pathways and is thought to be involved in allergic diseases, autoimmune diseases, and inflammatory diseases (Non-Patent Document 1). For example, BTK plays an important role in signal transduction of the high-affinity IgE receptor (FcεRI) in mast cells, and mast cells lacking BTK are known to exhibit reduced degranulation and reduced production of proinflammatory cytokines (Non-Patent Document 4). Furthermore, ibrutinib, an irreversible BTK inhibitor, is an anticancer drug used to treat B-cell tumors. Recently, it has been revealed that the C481S mutation in BTK causes ibrutinib resistance during ibrutinib treatment (Non-Patent Document 5). Recently, it has been reported that the isoform p65BTK is expressed downstream of RAS signaling in solid cancers other than blood cancers and has a profound impact on the proliferation of solid cancers such as colon cancer cells (Non-Patent Document 6). Therefore, compounds with BTK inhibitory activity are thought to be useful in the treatment of diseases in which BTK signaling is involved, such as cancer, B-cell lymphoma, and chronic lymphocytic leukemia, as well as in the treatment of solid cancers in which p65BTK is expressed.Additionally, oxoisoquinoline derivatives and triazine derivatives with reversible BTK inhibitory activity have been reported as reversible BTK inhibitors that are effective against cancers with BTK mutations that are resistant to irreversible BTK inhibitors such as ibrutinib (Patent Documents 1 and 2).

[0003] Meanwhile, in recent years, cancer immunotherapy has attracted attention in cancer treatment, using immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) antibodies, anti-PD-1 (programmed death receptor 1) antibodies, and anti-PD-L1 (programmed death ligand 1) antibodies to enhance the host's anti-tumor immune response and achieve anti-tumor effects. Several immune checkpoint inhibitors have been approved as pharmaceuticals, and their anti-tumor effects have been confirmed; however, only a limited number of patients are affected, and it has also been reported that some patients develop resistance to these inhibitors (Non-Patent Document 7). Recently, it has been reported that BTK inhibitors improve tumor immunity and, when used in combination with immune checkpoint inhibitors, exhibit synergistic anti-tumor effects (Non-Patent Documents 8, 9, 10). Therefore, BTK inhibitors activate immune cells and stimulate the immune system, making them useful not only for cancer treatment as cancer immunotherapy, but also for expanding and enhancing the therapeutic effects of conventional cancer immunotherapy when used in combination with immune checkpoint inhibitors, etc.

[0004] Chimeric antigen receptor-expressing T cell (CAR-T cell) therapy has also attracted attention as a type of antibody-free cancer immunotherapy. However, while CAR-T cell therapy exhibits high therapeutic efficacy against hematological cancers, it has not been sufficiently effective against solid cancers. BTK inhibitors have been reported to enhance the function of CAR-T cells and improve their antitumor effects (Non-Patent Document 11). Therefore, BTK inhibitors, when used in combination with CAR-T cell therapy, are useful for expanding and enhancing the therapeutic effects. As mentioned above, there have been reports on the activation of tumor immunity using the irreversible BTK inhibitor ibrutinib and its combination with cancer immunotherapy. However, there has been no disclosure of the combination of the reversible BTK inhibitor of the present invention with cancer immunotherapy, nor has there been any report on the enhancement of antitumor effects by combining the reversible BTK inhibitor of the present invention with an immune checkpoint inhibitor.

[0005] International Publication No. 2018 / 097234 International Publication No. 2015 / 012149

[0006] Satterthwaite, A. B. and Witte, O. N. , Immunol. Rev. , 2000, 175, 120-127. Kurosaki, T. , Curr. Open. Immunol. , 2000, 12, 276-281. Davis, R. E. , et al. , Nature, 2010, 463, 88-92. Ellmeier, W. , et al. , FEBS J., 2011, 278, 1990-2000. Cheng, S., et al., Leukemia, 2014, 1-6. Grassili. E. , et al. , Oncogene, 2016, 35, 4368-4378. Spranger, S. and Gajewski, T. F. , Nat. Rev. Cancer. , 2018, 18, 139-147. Sagiv-Barfi, I. , et al. , Proc. Natl. Acad. Sci. U. S. A.. 2015, 112, E966-E972. Gunderson, A. J. , et al. , Cancer Discov. , 2016, 6, 270-285. Stiff, A. , et al. , Cancer Res. , 2016, 76, 2125-2136. Wang, L. , et al. , Int. Immunopharmacol. , 2019, 70, 498-503.

[0007] The present invention aims to discover a more effective cancer treatment method by combining a cancer immunotherapy method with a reversible BTK inhibitor, and to provide a new pharmaceutical composition for cancer treatment.

[0008] As a result of intensive research to solve the above problems, the present inventors have found that the problems of the present invention can be solved by combining a compound represented by the below-described general formula (I) or (II) or a pharmaceutically acceptable salt thereof with an immune checkpoint inhibitor, and have completed the present invention. More specifically, the present invention relates to the following.

[0009] (1) A pharmaceutical composition for cancer treatment comprising a combination of a reversible BTK inhibitor and an immune checkpoint inhibitor. (2) The reversible BTK inhibitor is represented by the following formula (I): (In the formula, R 1represents a lower alkyl group which may have a substituent, and Q represents a structure selected from the following structures (a), (b), and (c): R 2 and R 3 and each independently represent a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or an optionally substituted heterocyclic group.

[0010] (3) The Q is structure (a), and R 1 (4) The pharmaceutical composition according to (2), wherein the reversible BTK inhibitor is a compound represented by the following formula (Ia): (In the formula, R 3a (5) The pharmaceutical composition according to (1), wherein the oxoisoquinoline derivative is an oxoisoquinoline derivative represented by the formula (IA): 2-(3-{2-amino-6-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one The pharmaceutical composition according to (4), having the structure (IA):

[0011] (6) The reversible BTK inhibitor is represented by the following formula (II): (In the formula, Z 1 represents a lower alkyl group which may have a substituent; Z 2 represents a hydrogen atom or a lower alkyl group which may have a substituent; A represents a nitrogen atom or C-Z 3 represents Z 3 represents a hydrogen atom, a cyano group, an acyl group which may have a substituent, a sulfonyl group which may have a substituent, or a carbamoyl group which may have a substituent; Z 4(7) The pharmaceutical composition according to (1), wherein the triazine derivative is represented by the formula: 1 (8) The pharmaceutical composition according to (6), wherein the triazine derivative is a compound (II-A): Formula (II-A): 2-(3-{4-amino-6-[(1-methyl-1H-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one The pharmaceutical composition according to (6), having the structure (II-A):

[0012] (9) The pharmaceutical composition according to any one of (1) to (8), wherein the immune checkpoint inhibitor is an inhibitor of an immune checkpoint molecule selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, TIM3, BTLA, B7H3, B7H4, CD160, CD39, CD73, A2aR, KIR, VISTA, IDO1, Arginase I, TIGIT, and CD115. (10) The pharmaceutical composition according to (9), wherein the immune checkpoint inhibitor is an anti-PD-1 antibody. (11) The pharmaceutical composition according to (9), wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody. (12) The pharmaceutical composition according to (9), wherein the immune checkpoint inhibitor is an anti-PD-L2 antibody. (13) The pharmaceutical composition according to (9), wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody. (14) Use of compound (I) and an immune checkpoint inhibitor for producing the pharmaceutical composition according to (1). (15) A method for treating cancer, characterized by using the pharmaceutical composition according to any one of (1) to (13).

[0013] The combination of a reversible BTK inhibitor and an immune checkpoint inhibitor can produce anti-cancer effects more efficiently than when either the BTK inhibitor or the immune checkpoint inhibitor is used alone. Therefore, the combination of a BTK inhibitor and an immune checkpoint inhibitor is expected to have a synergistic anti-cancer effect and is useful for preventing or treating cancer, etc.

[0014] We demonstrate that a reversible BTK inhibitor (I-A) inhibits tumor growth both as a single agent and in combination with an anti-PD-1 antibody in an allograft mouse model of the mouse colon cancer cell line CT26.WT (Example 1). We also demonstrate that a reversible BTK inhibitor (I-A) exerts a high antitumor effect in combination with an anti-PD-1 antibody in an allograft mouse model of the mouse B-cell lymphoma cell line A20 (Example 2).

[0015] (1) Reversible BTK Inhibitor One embodiment of the reversible BTK inhibitor is an oxoisoquinoline derivative represented by the following formula (I) described in International Publication No. 2018 / 097234 (Patent Document 1): (In the formula, R 1 represents a lower alkyl group which may have a substituent, and Q represents a structure selected from the following structures (a), (b), and (c): R 2 and R 3 each independently represent a hydrogen atom, an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, or an optionally substituted heterocyclic group) or a pharmaceutically acceptable salt thereof.

[0016] In formula (I) of the present specification, the lower alkyl group moiety of the optionally substituted lower alkyl group may be any linear or branched alkyl group having 1 to 3 carbon atoms, and specific examples thereof include a methyl group, an ethyl group, an isopropyl group, etc. The cycloalkyl group moiety of the optionally substituted cycloalkyl group may be any cyclic alkyl group having 3 to 6 carbon atoms, and specific examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclohexyl group, etc. The aryl group moiety of the optionally substituted aryl group may be any monocyclic or bicyclic aryl group having 6 to 14 carbon atoms, and the bicyclic aryl group may be partially hydrogenated. Specific examples thereof include a phenyl group, a naphthyl group, a tetrahydronaphthyl group, an indenyl group, etc.

[0017] The heteroaryl group moiety of the heteroaryl group, which may have a substituent, includes monocyclic aromatic heterocyclic groups and heterocyclic aromatic fused ring groups. Examples of monocyclic aromatic heterocyclic groups include 5- or 6-membered monocyclic aromatic heterocyclic groups containing at least one heteroatom selected from a nitrogen atom, a sulfur atom, and an oxygen atom. Specific examples include pyrrolyl, imidazolyl, pyrazolyl, thienyl, thiazolyl, furanyl, pyridyl, pyrimidyl, and pyridazyl. Examples of heterocyclic aromatic fused rings include bicyclic fused heterocyclic groups containing at least one heteroatom selected from a nitrogen atom, a sulfur atom, and an oxygen atom, each of which has 3 to 8 fused rings. Specific examples include tetrahydroisoquinolyl, benzothiophenyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, and isoquinolyl.

[0018] The heterocyclic group moiety of the optionally substituted heterocyclic group is a 4- to 6-membered monocyclic saturated heterocyclic group containing at least one heteroatom selected from a nitrogen atom, a sulfur atom, and an oxygen atom, and may have a partial unsaturated bond within the ring. Specific examples include a dihydrothiopyranyl group, a 1,1-dioxo-dihydrothiopyranyl group, and a tetrahydropyridyl group, with a tetrahydropyridyl group being particularly preferred. Unless otherwise specified, the "optionally substituted" substituents of an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted aryl group, an optionally substituted heteroaryl group, and an optionally substituted heterocyclic group may have one or more substituents of any type at any chemically feasible position, and when there are two or more substituents, the respective substituents may be the same or different.

[0019] Examples of the substituent of the optionally substituted lower alkyl group include a halogen atom, a C1-C4 alkoxy group, an amino group optionally substituted with one or two C1-C4 alkyl groups, a nitro group, a cyano group, a hydroxy group, a carbamoyl group optionally substituted with one or two C1-C4 alkyl groups, a carboxyl group, a formyl group, an acetyl group, a mesyl group, a benzoyl group, a C1-C6 acylamino group, a C1-C6 acyloxy group, etc. An example of the optionally substituted lower alkyl group is a hydroxymethyl group.

[0020] Examples of the "optionally substituted" substituents of the optionally substituted cycloalkyl group, optionally substituted aryl group, optionally substituted heteroaryl group, and optionally substituted heterocyclic group include a halogen atom, an oxygen atom, a C1-C4 alkyl group, a C1-C4 alkoxy group, an amino group optionally substituted with one or two C1-C4 alkyl groups, a nitro group, a cyano group, a hydroxy group, a carbamoyl group optionally substituted with one or two C1-C4 alkyl groups, a sulfonyl group optionally substituted with a C1-C4 alkyl group, a carboxyl group, a formyl group, an acetyl group, a mesyl group, a benzoyl group, an oxetanyl group, a C1-C6 acylamino group, and a C1-C6 acyloxy group.

[0021] Compound (I) may exist as an isomer, depending on, for example, the type of substituent. Although the present specification may refer to the chemical structure of only one form of such isomer, the present invention encompasses all structurally possible isomers (e.g., geometric isomers, optical isomers, tautomers), as well as individual isomers or mixtures thereof. Pharmaceutically acceptable salts of Compound (I) include inorganic acid salts with hydrochloric acid, sulfuric acid, carbonic acid, phosphoric acid, etc., and organic acid salts with fumaric acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid, etc. Other examples include alkali metal salts with sodium, potassium, etc., alkaline earth metal salts with magnesium, calcium, etc., organic amine salts with triethylamine, ethanolamine, etc., basic amino acid salts with lysine, arginine, ornithine, etc., as well as ammonium salts.

[0022] Compound (I) and pharmaceutically acceptable salts thereof can be produced, for example, by the method described in Patent Document 1. In the production method described in Patent Document 1, if the defined groups change under the conditions of the method or the method is unsuitable for carrying out, the compound can be easily produced by applying a method commonly used in organic synthetic chemistry, such as protection and deprotection of functional groups [T. W. Greene, Protective Groups in Organic Synthesis 3rd Edition, John Wiley & Sons, Inc., 1999]. Furthermore, the order of reaction steps such as the introduction of substituents can be changed as necessary.

[0023] The compounds of formula (I) above are preferably those in which Q is of the structure (a), R 1 is a hydroxymethyl group, and more preferably compound (IA): 2-(3-{2-amino-6-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one. (IA) Here, compound (IA) is the compound of Example 23 of Patent Document 1.

[0024] Another embodiment of the reversible BTK inhibitor is a compound represented by the following formula (II): (In the formula, Z 1 represents a lower alkyl group which may have a substituent; Z 2 represents a hydrogen atom or a lower alkyl group which may have a substituent; A represents a nitrogen atom or C-Z 3 represents Z 3 represents a hydrogen atom, a cyano group, an acyl group which may have a substituent, a sulfonyl group which may have a substituent, or a carbamoyl group which may have a substituent; Z 4 represents a lower alkyl group which may have a substituent, or a cycloalkyl group which may have a substituent.) or a pharmaceutically acceptable salt thereof.

[0025] In compound (II), the lower alkyl group moiety of the optionally substituted lower alkyl group may be any of linear, branched, or cyclic alkyl groups having 1 to 3 carbon atoms, and specific examples thereof include a methyl group, an isopropyl group, etc. The cycloalkyl group moiety of the optionally substituted cycloalkyl group may be any of cyclic alkyl groups having 3 to 6 carbon atoms, and specific examples thereof include a cyclopropyl group, a cyclobutyl group, etc. The acyl group moiety of the optionally substituted acyl group may be any of linear, branched, and cyclic alkyl groups and aryl groups bonded to a carbonyl group, and specific examples thereof include a formyl group, an acetyl group, a propionyl group, an octanoyl group, a dodecanoyl group, a pivaloyl group, a cyclopropylcarbonyl group, a benzoyl group, etc.

[0026] Examples of sulfonyl groups which may have a substituent include a methylsulfonyl group and an ethylsulfonyl group. Examples of carbamoyl groups which may have a substituent include a methylcarbamoyl group, an ethylcarbamoyl group, and a dimethylcarbamoyl group. The "optionally substituted" substituents of an optionally substituted lower alkyl group, an optionally substituted cycloalkyl group, an optionally substituted acyl group, an optionally substituted sulfonyl group, and an optionally substituted carbamoyl group, unless otherwise specified, may have one or more substituents of any type at any chemically possible position. When there are two or more substituents, the respective substituents may be the same or different, and examples thereof include a halogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted amino group, a nitro group, a cyano group, a hydroxy group, a substituted or unsubstituted alkylamino group, a substituted or unsubstituted carbamoyl group, a carboxyl group, a formyl group, an acetyl group, a mesyl group, a benzoyl group, a substituted or unsubstituted acylamino group, and a substituted or unsubstituted acyloxy group.

[0027] Compound (II) may have isomers, for example, depending on the type of substituent. Although the present specification may describe only one form of the chemical structure of these isomers, the present invention also includes all structurally possible isomers (geometric isomers, optical isomers, tautomers, etc.), as well as single isomers or mixtures thereof. Pharmaceutically acceptable salts of compound (II) include inorganic acid salts with hydrochloric acid, sulfuric acid, carbonic acid, phosphoric acid, etc., organic acid salts with fumaric acid, maleic acid, methanesulfonic acid, p-toluenesulfonic acid, etc. Other examples include alkali metal salts with sodium, potassium, etc., alkaline earth metal salts with magnesium, calcium, etc., organic amine salts with lower alkylamines, lower alcoholamines, etc., basic amino acid salts with lysine, arginine, ornithine, etc., as well as ammonium salts.

[0028] Compound (II) and pharmaceutically acceptable salts thereof can be produced, for example, by the method described in Patent Document 2. In the production method described in Patent Document 2, if the defined groups change under the conditions of the method or the method is unsuitable for carrying out, the compound can be easily produced by applying a method commonly used in organic synthetic chemistry, such as protection and deprotection of functional groups [T. W. Greene, Protective Groups in Organic Synthesis 3rd Edition, John Wiley & Sons, Inc., 1999]. Furthermore, the order of reaction steps such as the introduction of substituents can be changed as necessary.

[0029] The compound of the formula (II) is preferably a compound in which A is a nitrogen atom, Z 1 is a hydroxymethyl group, and more preferably, it is compound (II-A): 2-(3-{4-amino-6-[(1-methyl-1H-pyrazol-4-yl)amino]-1,3,5-triazin-2-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one. (II-A) Here, the compound (II-A) is the compound of Example 1 of Patent Document 2.

[0030] (2) Immune Checkpoint Inhibitors In the present invention, an immune checkpoint inhibitor is a substance that inhibits the function of an immune checkpoint molecule acting on the immune checkpoint system, and is not particularly limited as long as it has immune checkpoint inhibitory activity. The immune checkpoint molecule may be any molecule that controls the immune checkpoint system, and is not limited thereto. Examples of immune checkpoint molecules include immune checkpoint molecules known in the literature (see, for example, Qin et al., Molecular Cancer, 2019, 18, 155), specifically PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, TIM3, BTLA, B7H3, B7H4, CD160, CD39, CD73, A2aR, KIR, VISTA, IDO1, Arginase I, TIGIT, and CD115.

[0031] Immune checkpoint inhibitors are substances that inhibit the function of human immune checkpoint molecules, and examples include neutralizing antibodies. Examples of immune checkpoint inhibitors include, but are not limited to, the following. Specific examples include anti-PD-1 antibodies (e.g., nivolumab, pembrolizumab, etc.), anti-PD-L1 antibodies (e.g., avelumab, atezolizumab, durvalumab, etc.), anti-PD-L2 antibodies, and anti-CTLA-4 antibodies (ipilimumab, tremelimumab, etc.). Furthermore, in the present invention, any one or more of these immune checkpoint inhibitors can be used in combination with the reversible BTK inhibitor used in the present invention.

[0032] (3) Combined Pharmaceutical Compositions The pharmaceutical compositions of the present invention are compositions that appropriately combine a reversible BTK inhibitor and an immune checkpoint inhibitor, and include kits comprising the BTK inhibitor and the immune checkpoint inhibitor. The two inhibitors may be administered simultaneously, either as a mixed formulation or as separate formulations. Alternatively, they may be administered individually in any order, sequentially, or with an appropriate time interval. The dosages of the reversible BTK inhibitor and immune checkpoint inhibitor used in the present invention can be varied depending on the administration method (oral administration, parenteral administration, or topical administration), the type of disease to which they are applied, the severity of the disease, the age and weight of the patient, etc.

[0033] The dosage of the reversible BTK inhibitor used in the present invention is typically in the range of 0.01 mg to 1,000 mg per day in an adult, and can be administered orally or parenterally in a single dose, or in two or three divided doses. The dosage of the immune checkpoint inhibitor used in the combination of the present invention varies depending on the dosage of the reversible BTK inhibitor used in the present invention, the method of administration (oral administration, parenteral administration, or topical administration), the type of disease to be treated, the severity of the disease, the age and weight of the patient, etc., and can be adjusted to obtain the optimal desired effect. However, the dosage is typically in the range of 0.1 mg to 20 mg / kg per day in an adult, and is administered parenterally (e.g., continuous intravenous infusion).

[0034] The combination of the present invention can be administered simultaneously in the same or different dosage forms, or separately. The pharmaceutical composition of the combination of the present invention is useful for cancer treatment, including hematological cancers (e.g., leukemia, malignant lymphoma, multiple myeloma, myelodysplastic syndrome, etc.), solid cancers (e.g., gastric cancer, colon cancer, lung cancer, esophageal cancer, liver cancer, breast cancer, ovarian cancer, uterine cancer, renal cancer, prostate cancer, skin cancer, etc.), osteosarcoma, mesothelioma, and cancer of unknown primary origin. The pharmaceutical composition of the combination of the present invention is expected to have an antitumor effect in cancer patients who do not respond sufficiently to treatment with a reversible BTK inhibitor or immune checkpoint inhibitor alone. Furthermore, the enhanced antitumor effect of the combination of the present invention allows for a reduction in the dosage of each drug, thereby reducing side effects and other adverse reactions. The combination of the present invention is also expected to be effective in suppressing cancer metastasis and recurrence, and in treating metastatic cancer.

[0035] Example 1: Effect of Combination of Reversible BTK Inhibitor and Anti-PD-1 Antibody in an Allograft Mouse Model of the Mouse Colon Cancer Cell Line CT26.WT The antitumor effect of the compound according to the present invention was examined using a syngeneic mouse tumor model (subcutaneous transplant) of the mouse colon cancer cell line CT26.WT. (Culture of Cells Used) A cell culture medium was prepared by adding 10% FBS (Biowest) and 1% penicillin-streptomycin (Nacalai) to RPMI-1640 medium (Life Technologies, No. A1049101) (hereinafter referred to as Medium 1). CT26.WT cells (ATCC) were cultured in a flask using Medium 1 under 5% CO 2 The tumor-bearing model was cultured in an incubator at a cell density of 5 × 10 CT26.WT cells. 6 The cells were adjusted with RPMI-1640 medium (containing 1% penicillin streptomycin, hereinafter referred to as medium 2) to a concentration of 100 cells / mL to prepare a cell preparation solution for transplantation. 0.1 mL of this cell preparation solution for transplantation was transplanted subcutaneously into the dorsal skin of BALB / cCrslc mice (female, 8 weeks old, Japan SLC). Three days after the cancer cell transplantation, the tumor-bearing mice were divided into groups so that the mean tumor volume (see calculation formula below) was similar.

[0036] (Preparation of sample solution for administration of test substance) A 1.5 mg / mL solution was prepared as the sample solution for administration of the test substance. The test substance (71.9 mg) was dissolved in DMSO (2.4 mL, Nacalai Tesque), polyethylene glycol #400 (24.0 mL, Nacalai Tesque) was added and mixed well, and then 21.5 mL of a 30% (w / v) aqueous solution of 2-hydroxypropyl-β-cyclodextrin (HP-β-CD, Wacker Chemical) was added to prepare a 1.5 mg / mL sample solution for administration. (Preparation of antibody solution) An anti-PD-1 antibody (Bio X Cell, clone RMP1-14; catalog No. BE0146) was prepared with saline to a concentration of 1 mg / mL immediately before administration.

[0037] (Antitumor Effect Test of Test Substances) Mice (six per group) transplanted with cancer cells were orally administered 0.1 mL of the test substance (15 mg / kg) or vehicle per 10 g of body weight on the day twice daily (at least 6 hours apart) from day 3 to day 21 after transplantation. Drug-free periods were observed on days 8, 9, 15, and 16 after transplantation. Furthermore, the antibody-administered group and the drug-combined group received 0.1 mL of antibody solution (10 mg / kg) per 10 g of body weight on the day twice weekly (six times in total), while the other groups received saline. After transplantation, mice were observed for 48 days, with tumor diameters measured several times a week. The tumor volume of each mouse was calculated using the following formula to evaluate the antitumor effect. Figure 1 shows the change in tumor volume over time in each group. As shown in Figure 1, the BTK inhibitor (I-A) inhibited tumor growth as a single agent, and when used in combination with an anti-PD-1 antibody, it exhibited significant tumor growth inhibition and tumor regression effects. Furthermore, in the combination group, complete tumor regression was observed in five of six mice implanted with tumors. This confirms that the combination of a reversible BTK inhibitor and an immune checkpoint inhibitor according to the present invention exhibits excellent antitumor effects and is useful in cancer treatment.

[0038] Example 2: Effect of Combination of Reversible BTK Inhibitor and Anti-PD-1 Antibody in an Allograft Mouse Model of Mouse B-Cell Lymphoma Cell Line A20 The antitumor effect of the compound according to the present invention was examined using a syngeneic mouse tumor model (subcutaneous transplant) of the mouse B-cell lymphoma cell line A20. (Culture of Cells Used) A cell culture medium was prepared by adding 10% FBS (HyClone), 0.05 mM 2-mercaptoethanol, and 1% penicillin-streptomycin (Nacalai) to RPMI-1640 medium (Life Technologies, No. A1049101) (hereinafter referred to as Medium 3). A20 cells (ATCC) were cultured in a flask using Medium 3 under 5% CO 2 The cells were cultured in an incubator. (Preparation of tumor-bearing model) A20 cells were cultured at a cell density of 5 × 10 7 The cell preparation solution for transplantation was prepared by adjusting the cell density with Medium 2 to cells / mL. 0.1 mL of this cell preparation solution for transplantation was subcutaneously transplanted into the dorsal skin of BALB / cCrslc mice (female, 8 weeks old, Japan SLC). Three days after the cancer cell transplantation, the tumor-bearing mice were divided into groups so that the mean tumor volumes (see Formula 1 in Example 1) were similar.

[0039] (Antitumor Effect Test of Test Substances) Mice (six mice per group) implanted with cancer cells were orally administered 0.1 mL of the test substance (15 mg / kg) or vehicle per 10 g of body weight on that day by gavage twice daily (at least 6 hours apart) from days 3 to 14 after implantation. Days 8 and 9 after implantation were treated with a rest period. Furthermore, the antibody-administered group and the drug-combined group received 0.1 mL of antibody solution (10 mg / kg) per 10 g of body weight on that day intraperitoneally twice weekly (a total of four times). Other groups received saline. After implantation, mice were observed for 46 days. Tumor diameters were measured several times a week, and tumor volumes for each mouse were calculated using the same formula as in Example 1 to evaluate the antitumor effect. Tumors were excised from each mouse on day 46 after implantation, and tumor weights were measured. Figure 2 shows the tumor weights for each group on day 46 after implantation. As shown in Figure 2, the BTK inhibitor (I-A), when used in combination with an anti-PD-1 antibody, exhibited significant tumor growth suppression and tumor regression effects, with complete tumor regression observed in five of six mice implanted with tumors. This demonstrates that the combination of the reversible BTK inhibitor of the present invention with an immune checkpoint inhibitor exhibits excellent antitumor effects and is useful in cancer treatment.

[0040] The combination of the reversible BTK inhibitor and immune checkpoint inhibitor of the present invention is useful for cancer treatment because it can achieve a strong antitumor effect due to the combined effect.

Claims

1. The following formula (Ia): 【Chemistry 1】 (In the formula, R 3a represents a tetrahydropyridyl group which may have a substituent.) or a pharma- ceutical composition for cancer treatment, comprising a combination of a reversible BTK inhibitor, which is an oxoisoquinoline derivative represented by the following formula:

2. The oxoisoquinoline derivative is compound (IA): Formula (IA): 2-(3-{2-amino-6-[1-(oxetan-3-yl)-1,2,3,6-tetrahydropyridin-4-yl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}-2-(hydroxymethyl)phenyl)-6-cyclopropyl-8-fluoroisoquinolin-1(2H)-one 【Chemistry 2】 (I-A) The pharmaceutical composition of claim 1 having the structure:

3. The pharmaceutical composition according to any one of claims 1 or 2, wherein the immune checkpoint inhibitor is an inhibitor of an immune checkpoint molecule selected from the group consisting of PD-1, PD-L1, PD-L2, CTLA-4, LAG-3, TIM3, BTLA, B7H3, B7H4, CD160, CD39, CD73, A2aR, KIR, VISTA, IDO1, Arginase I, TIGIT and CD115.

4. The pharmaceutical composition according to claim 3, wherein the immune checkpoint inhibitor is an anti-PD-1 antibody.

5. The pharmaceutical composition according to claim 3, wherein the immune checkpoint inhibitor is an anti-PD-L1 antibody.

6. The pharmaceutical composition according to claim 3, wherein the immune checkpoint inhibitor is an anti-PD-L2 antibody.

7. The pharmaceutical composition of claim 3, wherein the immune checkpoint inhibitor is an anti-CTLA-4 antibody.

8. Use of compound (Ia) and an immune checkpoint inhibitor for the manufacture of the pharmaceutical composition according to claim 1.